If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksForterra Regulatory News (FORT)

Share Price Information for Forterra (FORT)

Share Price is delayed by 15 minutes
Get Live Data
138.20    1.20 (0.88%)
Bid:
138.00
Ask:
138.60
Spread: 0.60 (0.435%)
Market Cap: £283.44m
FORT Live PriceLast checked at - London Stock Exchange

Intraday Forterra Share Chart

2023 Trading Update

24 Jan 2024 07:00

RNS Number : 6815A
Forterra plc
24 January 2024
 

24 January 2024

FORTERRA PLC

 

2023 Trading Update

 

Adjusted EBITDA expected to be slightly ahead of the Board's previous expectations

 

Forterra plc (the 'Group'), a leading UK manufacturer of essential clay and concrete building products, provides its trading update for the year ended 31 December 2023.

 

Trading

 

· Full year revenue totalled c.£345m (2022: £455m), a year-on-year reduction of c.24%, with the impact of falling sales volumes partially offset by pricing benefits.

 

· Despite weak demand, pricing across our range of products remains resilient with modest 2024 price increases recently communicated.

 

· Figures published by the Department of Business and Trade highlight that UK brick despatches in the three-month period to November were 33% lower than the equivalent period in 2022, taking the cumulative YTD reduction to approximately 30%. As highlighted previously, our own despatches fell by a greater percentage driven by our exposure to volume housebuilding which suffered the greatest impact from rising interest rates.

 

· Despite continued challenging market conditions we expect to report full year adjusted EBITDA slightly ahead of the Board's expectations.

 

Management Actions

 

· Strong management actions during the year will deliver annualised fixed costs savings in excess of £20m with around £6m realised in 2023 with the balance in 2024. One-off cash restructuring costs are expected to total £9m of which £4m will be paid in 2024.

 

· Faced with increasing inventory levels, we made further reductions to production during the second half of 2023 which, assuming 2024 demand remains consistent with 2023, will ensure output is aligned with sales.

 

· Production has been reduced through the mothballing of factories, shift reductions and production breaks. In addition, we have delivered further savings through restructuring commercial and back-office functions.

 

· These temporary reductions will not impact our ability to respond quickly when our markets recover, with the new Desford brick factory also providing us with a significant capacity uplift.

 

Balance Sheet

 

· Reflecting our inventory build, capital expenditure and the management actions taken during 2023, year-end net debt before leases is expected to be c.£95m.

 

Outlook

 

· The outlook for our industry remains subject to considerable uncertainty and, with a general election expected in 2024, demand is anticipated to remain subdued in the near term.

 

· However, with the long term under supply of housing in the UK continuing to worsen, and UK brick despatches now running at levels last seen in 2009, the Board remains confident in the Group's ability to benefit as our key markets recover.

 

· Recent reductions in mortgage interest rates will improve the affordability of new homes, thus increasing demand for our products.

 

· The Group intends to announce its FY23 results on 26 March 2024.

 

 

ENQUIRIES

 

 

Forterra plc

+44 1604 707 600

Neil Ash, Chief Executive Officer

Ben Guyatt, Chief Financial Officer

FTI Consulting

+44 203 727 1340

Richard Mountain / Nick Hasell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUOVWRSWUAUAR
Date   Source Headline
11th Mar 20267:00 amRNSFull Year Results
3rd Mar 20263:27 pmRNSEmployee Benefit Trust Share Purchase
18th Feb 20262:27 pmRNSEmployee Benefit Trust Share Purchase
3rd Feb 202612:26 pmRNSEmployee Benefit Trust Share Purchase
29th Jan 20268:33 amRNSHolding(s) in Company
28th Jan 20269:21 amRNSHolding(s) in Company
26th Jan 20264:07 pmRNSHolding(s) in Company
22nd Jan 20267:00 amRNSFull Year 2025 Trading Update
20th Jan 20267:00 amRNSEmployee Benefit Trust Share Purchase
7th Jan 20269:39 amRNSEmployee Benefit Trust Share Purchase
2nd Dec 20259:22 amRNSEmployee Benefit Trust Share Purchase
24th Nov 20259:03 amRNSHolding(s) in Company
20th Nov 20259:13 amRNSHolding(s) in Company
18th Nov 20255:03 pmRNSEmployee Benefit Trust Share Purchase
11th Nov 20257:00 amRNSTrading Update
4th Nov 20254:34 pmRNSEmployee Benefit Trust Share Purchase
24th Oct 20251:36 pmRNSHolding(s) in Company
23rd Oct 20251:21 pmRNSDirector/PDMR Shareholding
17th Oct 20259:58 amRNSEmployee Benefit Trust Share Purchase
14th Oct 20259:06 amRNSHolding(s) in Company
13th Oct 202510:15 amRNSEmployee Benefit Trust Share Purchase
2nd Oct 20252:54 pmRNSGrant of Options under 2025 SAYE Scheme
11th Aug 20251:15 pmRNSHolding(s) in Company
29th Jul 20257:38 amRNS-RProgressive publishes new research
29th Jul 20257:00 amRNSSix months ended 30 June 2025
23rd Jul 202510:05 amRNSHolding(s) in Company
19th Jun 20257:05 amRNSDirector Declaration
20th May 20251:47 pmRNSAnnual General Meeting 2025 Results
20th May 20257:43 amRNS-RProgressive publishes new research
20th May 20257:00 amRNSAGM Trading Update
13th May 202510:36 amRNSHolding(s) in Company
11th Apr 20259:18 amRNSDirector / PCA Shareholdings
2nd Apr 20252:22 pmRNSDirector/PDMR Shareholding
26th Mar 20255:53 pmRNSAnnual Report & Accounts 2024 & Notice of AGM 2025
25th Mar 20251:47 pmRNSDirector/PDMR Shareholding
20th Mar 20252:44 pmRNSHolding(s) in Company
20th Mar 20257:00 amRNSGrant under Performance Share Plan
20th Mar 20257:00 amRNSGrant under Deferred Annual Bonus Plan
18th Mar 20252:23 pmRNSHolding(s) in Company
12th Mar 20258:14 amRNS-RProgressive publishes new research
12th Mar 20257:00 amRNSFull Year Results
6th Mar 20257:00 amRNSAppointment of Independent Non-Executive Director
27th Feb 20253:35 pmRNSHolding(s) in Company
26th Feb 20252:50 pmRNSHolding(s) in Company
4th Feb 20257:00 amRNSDirectorate Change
23rd Jan 20257:00 amRNSFull Year 2024 Trading Update
6th Jan 20259:23 amRNSHolding(s) in Company
2nd Jan 202511:38 amRNSDirector/PDMR Shareholding
11th Nov 20247:00 amRNSTrading update to the end of the October
4th Nov 202410:24 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.